More

    DCGI approval for Bharat Biotech’s nasal booster dose trials

    HealthCOVID-19DCGI approval for Bharat Biotech’s nasal booster dose trials
    - Advertisment -

    DCGI approval for Bharat Biotech’s nasal booster dose trials

    The producer of India’s indigenous vaccine, Covaxin, will now be able to conduct trials of its nasal vaccine as a booster dose at nine locations in the country.

    The Drug Controller General of India today gave its approval to Indian biotechnology-pharma company, Bharat Biotech, to conduct Phase-III clinical trials of a nasal vaccine it has developed. The trials of the intranasal booster dose will be conducted on people who have received both doses of Bharat Biotech’s Covaxin.

    Covaxin producer will now be able to conduct trials of its nasal vaccine as a booster dose at nine locations in the country.

    An intranasal vaccine has logistical advantages and will be easier to administer in mass vaccination drives. The company claims that the BBV154 vaccine stimulates a broad immune response, especially at the site of infection (in the nasal mucosa that lines the nasal cavity) – essential for blocking both infection and transmission of COVID-19.

    - Advertisement -

    Besides ease of administration – as it does not require trained health care workers, the nasal vaccine also eliminates risks of injuries and infections that might be associated with a needle administered jab. It can elicit a high degree of compliance, especially as it suits children and adults.

    The non-invasive and needle-free nasal route has excellent potential for vaccination due to the organised immune systems of the nasal mucosa.

    Biotechnology feat

    The biotechnology company has applied to the Drug Controller General of India for approval for phase-III trials of the BBV154 vaccine in December 2021.

    If given the green signal following the trials, Bharat Biotech claims it will be able to undertake large-scale to meet global demands.

    The attenuated avirulant vaccine comes from a modified chimpanzee adenovirus. (This is a harmless, weakened adenovirus that usually causes the common cold in chimpanzees.) In this respect, the operative biologicals of this vaccine are somewhat like the AstraZeneca vaccine that also uses a chimpanzee adenovirus vaccine vector that has been genetically changed to stop it from adversely affecting humans.

    According to the company, mice, hamsters and macaques immunized with a single dose of the vaccine “conferred superior protection against SARS-CoV-2 challenge”.

    It claims that intranasal immunization “can create an immune response in the nose, which is the point of entry for the virus—thereby protecting against disease, infection, and transmission.”

    - Advertisement -

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here

    Latest news

    Sri Lanka’s Elephant Corridor Plan ‘Unscientific’

    Nearly 5,000 elephants and 1,600 people have been killed in the last 15 years in clashes between elephants and humans in Sri Lanka, home to one of the largest remaining populations of Asian elephants, according to official figures.

    New Projections Show Extreme Glacier Loss Already at 2°C

    Staying close to 1.5°C on the other hand preserves at least some glacier ice in all regions, even Scandinavia, with 20-30 per cent remaining in the four most sensitive regions; and 40-45 per cent in the Himalayas and Caucuses; stressing the growing urgency of the 1.5°C temperature goal and rapid decarbonization to achieve it.

    Government Extends Interest Relief for Farmers, Reinforces KCC and MISS as Pillars of Agricultural Credit

    Through the KCC framework, farmers benefit from revolving credit facilities for up to five years. This flexible structure allows them to draw and repay funds as per their seasonal requirements without having to reapply for loans each season.

    Legal Battle Brews Over Rampant Illegal Sand Mining in Meghna River

    The massive profits coupled with a weak legal framework have drawn influential individuals with political connections into the sand mining business, making it dangerous for environmental activists and journalists to speak out.
    - Advertisement -

    Yunus Warns of ‘War-Like Situation’ Amid Political Crisis and Rising Tensions

    The high-stakes meeting brought together 20 leaders from various political parties and organisations in two separate sessions, as Yunus sought to shore up support amid reports of internal tensions within his interim government and growing external pressure.

    Vice President Calls for Direct Subsidies and Agri-Entrepreneurship at Madhya Pradesh Conclave

    He urged agro-based industries, NGOs, MPs, and MLAs to adopt villages and help build agri-entrepreneurial ecosystems.

    Must read

    Sri Lanka’s Elephant Corridor Plan ‘Unscientific’

    Nearly 5,000 elephants and 1,600 people have been killed in the last 15 years in clashes between elephants and humans in Sri Lanka, home to one of the largest remaining populations of Asian elephants, according to official figures.

    New Projections Show Extreme Glacier Loss Already at 2°C

    Staying close to 1.5°C on the other hand preserves at least some glacier ice in all regions, even Scandinavia, with 20-30 per cent remaining in the four most sensitive regions; and 40-45 per cent in the Himalayas and Caucuses; stressing the growing urgency of the 1.5°C temperature goal and rapid decarbonization to achieve it.
    - Advertisement -

    More from the sectionRELATED
    Recommended to you